Related Experiment Videos
[Treatment of hepatitis C]
1Medisinsk avdeling A Rikshospitalet, Oslo.
Insights
Hepatitis C virus (HCV) infection causes chronic liver disease globally. This survey reviews HCV diagnosis, current treatments, and identifies patients most likely to respond to therapy, emphasizing controlled study importance.
Area of Science:
- Hepatology
- Virology
- Clinical Medicine
Context:
- Hepatitis C virus (HCV) remains a significant global cause of chronic liver disease and post-transfusion hepatitis.
- Recent years have seen increased focus on managing chronic HCV infection, generating substantial data on disease progression with and without treatment.
Purpose:
- To survey the diagnosis of Hepatitis C virus infection.
- To present current treatment modalities for chronic HCV infection and discuss their therapeutic potential.
- To identify patient populations most likely to respond favorably to treatment.
Summary:
- This review covers diagnostic approaches for Hepatitis C virus.
- It details existing treatment options for chronic HCV infection, evaluating their efficacy and potential benefits.
- The survey also characterizes patients who exhibit higher treatment response rates and discusses the rationale for conducting further HCV treatment research within controlled studies.
Impact:
- Provides a comprehensive overview of Hepatitis C diagnosis and treatment strategies.
- Aids clinicians in identifying suitable candidates for HCV therapy.
- Highlights the necessity of continued research in controlled environments to advance HCV management and patient outcomes.
Abstract:
Hepatitis C virus (HCV) has been a major cause of post transfusion hepatitis, and is still an important cause of chronic liver disease throughout the world. How to treat patients with chronic HCV infection has been brought into focus in recent years, and a substantial amount of data has been obtained about the development of hepatitis C with and without treatment. This survey considers the diagnosis of hepatitis C, and present treatment modalities and their potential. The patients most likely to respond to treatment are described, and the authors finally discuss why treatment of hepatitis C still should take place in controlled studies.